Skip to main content
SpringerLink
Log in

Another look at trimethoprim-sulfamethoxazole: Its role in parenteral therapy

  • Editorial
  • Published:
European Journal of Clinical Microbiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Huovinen, P., Toivanen, P.: Trimethoprim resistance in Finland after five years use of plain trimethoprim. British Medical Journal 1980, 280: 72–74.

    PubMed  Google Scholar 

  2. Hamilton-Miller, J. M. T., Gooding, A., Brumfitt, W.: Resistance to trimethoprim in 1978–1979 compared with 1973–1975. Journal of Clinical Pathology 1981, 34: 439–442.

    PubMed  Google Scholar 

  3. O'Brien, T. F., Acar, J. F., Altmann, G., et al.: Laboratory surveillance of synergy between and resistance to trimethoprim and sulfonamides. Reviews of Infectious Diseases 1982, 4: 351–357.

    PubMed  Google Scholar 

  4. Pierson, C. L., Schaberg, D. R., Fekety, F. R., Jr., McClatchey, D. L.: In vitro activity of Sch 29482, MK0787, ceftriaxone, and seven other antimicrobials against 940 separate clinical isolates. Journal of Antimicrobial Chemotherapy 1982, 9 (Supplement C): 79–89.

    PubMed  Google Scholar 

  5. Spicehandler, J., Pollock, A. A., Simberkoff, M. S., Rahal, J. J., Jr.: Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim-sulfamethoxazole. Reviews of Infectious Diseases 1982, 4: 562–565.

    PubMed  Google Scholar 

  6. Parsley, T. L., Provonchee, R. G., Glicksman, C., Zinner, S. H.: Synergistic activity of trimethoprim and amikacin against gram-negative bacilli. Antimicrobial Agents and Chemotherapy 1975, 12: 349–352.

    Google Scholar 

  7. Paisley, J. W., Washington, J. A.: II. Synergistic activity of gentamicin with trimethoprim or sulfamethoxazoletrimethoprim againstEscherichia coli andKlebsiella. Antimicrobial Agents and Chemotherapy 1978, 14: 656–658.

    PubMed  Google Scholar 

  8. Wallace, R. J., Jr., Septimus, E. J., Williams, T. W., et al.: Use of trimethoprim-sulfamethoxazole for treatment of infections due toNocardia. Reviews of Infectious Diseases 1982, 4: 315–325.

    PubMed  Google Scholar 

  9. Winslow, D. L., Pankey, G. A.: In vitro activities of trimethoprim and sulfamethoxazole againstListeria monocytogenes. Antimicrobial Agents and Chemotherapy 1982, 22: 51–54.

    PubMed  Google Scholar 

  10. Prichard, M. G., Miles, H. M., Pavillard, E. R.:Listeria meningitis — in vitro sensitivities to co-trimoxazole, penicillins, and gentamicin. Australian and New Zealand Journal of Medicine 1983, 13: 76–77.

    PubMed  Google Scholar 

  11. Seger, R. A., Baumgartner, S., Tiefenauer, L. X., Gmünder, F. K.: Chronic granulomatous disease: Effect of sulfamethoxazole/trimethoprim on neutrophil microbicidal function. Helvetica Paediatrica Acta 1981, 36: 579–588.

    PubMed  Google Scholar 

  12. Lau, W. K., Young, L. S.: Trimethoprim-sulfamethoxazole treatment ofPneumocystis carinii pneumonia in adults. New England Journal of Medicine 1976, 295: 716–718.

    PubMed  Google Scholar 

  13. Miser, J. S., Savitch, J., Bleyer, W. A.: Management ofPseudomonas carinii pneumonia. New England Journal of Medicine 1977, 296: 4–7.

    Google Scholar 

  14. Grose, W. E., Bodey, G. P., Loo, T. L.: Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole. Antimicrobial Agents and Chemotherapy 1979, 15: 447–451.

    PubMed  Google Scholar 

  15. De la Cruz, A., Oleski, J., LaBraico, J., et al.: Correction of polymorphonuclear leukocyte chemotaxis defects with trimethoprim-sulfamethoxazole. In: Peviti, P., Grossi, G. (ed.): Current Chemotherapy and Immunotherapy, Proceedings of the 12th International Congress of Chemotherapy. Washington, DC, American Society of Microbiology, 1982, p. 185–186.

    Google Scholar 

  16. Grose, W. E., Bodey, G. P.: Intravenous trimethoprim-sulfamethoxazole alone or combined with tobramycin for infections in cancer patients. American Journal of the Medical Sciences 1980, 279: 4–13.

    PubMed  Google Scholar 

  17. Sattler, F. R., Remington, J. S.: Intravenous sulfamethoxazole and trimethoprim for serious gram-negative bacillary infection. Archives of Internal Medicine 1983, 142: 1709–1712.

    Google Scholar 

  18. Goodwin, N. M.: Intravenous Bactrim*: A preliminary report. South African Medical Journal 1973, 47: 2159–2161.

    PubMed  Google Scholar 

  19. Olcen, P., Ericksson, M.: The intravenous infusion of co-trimoxazole in cases of septicaemia: tolerance and results of treatment. Scandinavian Journal of Infectious Diseases 1976, 8 (Supplement 9): 91–94.

    PubMed  Google Scholar 

  20. Franzen, C., Brandberg, A.: Co-trimoxazole in cases of gram-negative septicemia. Scandinavian Journal of Infectious Diseases 1976, 8 (Supplement 8): 96–100.

    PubMed  Google Scholar 

  21. Stratford, B. C., Clarke, B. G., Dixon, S.: Intravenous co-trimoxazole therapy in serious infections. Medical Journal of Australia 1978, ii: 37–38.

    Google Scholar 

  22. Schmidt, U., Sen, P., Kapila, R., Louria, D. B.: Clinical evaluation of intravenous trimethoprim-sulfamethoxazole for serious infections. Reviews of Infectious Diseases 1982, 4: 332–337.

    PubMed  Google Scholar 

  23. The bacteriologic report — summer series 1983: BAC-DATA Medical Information Systems Inc., Totawa, H. M., 1983, p. 8.

  24. Yogev, R., Moxon, E. R.: Elaboration of type b capsule byHaemophilus influenzae as a determinant of pathogenicity and impaired killing by trimethoprim-sulfamethoxazole. Journal of Clinical Investigation 1982, 69: 658–665.

    PubMed  Google Scholar 

  25. Appelbaum, P. C., Tamim, J., Pankuch, G. A., Aber, R. C.: Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and azthreoman. Chemotherapy 1983, 29: 337–344.

    PubMed  Google Scholar 

  26. Sanders, C. C., Sanders, W. E., Jr.: Emergence of resistance during therapy with the newerβ-lactam antibiotics: Role of inducibleβ-lactamases and implications for the future. Reviews of Infectious Diseases 1983, 5: 639–648.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Milton S. Hershey Medical Center, 17033, Hershey, Pennsylvania, USA

    F. R. Sattler

  2. Department of Medicine, Stanford, University Medical Center, 94305, Stanford, California, USA

    J. S. Remington

Authors
  1. F. R. Sattler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. Remington
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sattler, F.R., Remington, J.S. Another look at trimethoprim-sulfamethoxazole: Its role in parenteral therapy. Eur. J, Clin. Microbiol. 3, 174–176 (1984). https://doi.org/10.1007/BF02014872

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02014872

Search

Navigation